Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vox Sang. 2007 May;92(4):319-26.

Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience.

Author information

  • 13rd Regional Blood Transfusion Centre, General Hospital G. Gennimatas, Athens, Greece. cpolitis@hol.gr

Abstract

BACKGROUND AND OBJECTIVES:

The objective of this paper is to present 5 years' experience of pathogen inactivation of fresh-frozen plasma with the methylene blue system in a blood centre in Athens.

MATERIALS AND METHODS:

Eight thousand and five hundred units treated by methylene blue and 54 435 untreated were issued for transfusion in four hospitals during the period 2000-2005. Eighty-eight units were evaluated for changes in coagulation factor activity and cytokine concentrations following treatment.

RESULTS:

Coagulation factor losses were in the accepted range. Adverse reactions were 1 : 8500 with treated and 1 : 2177 with untreated units. The five serious reactions were all in untreated units. No seroconversions for infectious diseases were reported.

CONCLUSIONS:

Methylene-blue-treated fresh-frozen plasma is safer than the untreated product even in patients who require large quantities of plasma transfusion.

PMID:
17456156
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk